No need to discontinue hepatitis C virus therapy at the time of liver transplantation

OBJECTIVES: Direct antiviral agents (DAA) has dramatically improved the therapy outcome of hepatitis C-virus (HCV) infection, both on the waiting-list and post liver transplantation (LT). DAA are generally well-tolerated in patients with mild to moderate liver and kidney failure, but some DAAs are c...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoglund, Catarina, Lagging, Martin, Castedal, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386281/
https://www.ncbi.nlm.nih.gov/pubmed/30794555
http://dx.doi.org/10.1371/journal.pone.0211437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386281/
https://www.ncbi.nlm.nih.gov/pubmed/30794555
http://dx.doi.org/10.1371/journal.pone.0211437

Ejemplares similares